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013.01.00Abstract Aim of the work: This study aimed to investigate serum levels of vitamin D in patients
with Behc¸et’s disease (BD) and to evaluate their relationship to disease activity as well as different
disease measures.
Patients and methods: Forty-two patients with BD were enrolled into this study. These patients
were subjected to detailed history taking, thorough clinical examination including assessment of dis-
ease activity according to Behc¸et’s Disease Current Activity Form (BDCAF) score and performed
laboratory investigations including erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), serum calcium, serum phosphorus and serum alkaline phosphatase. Serum 25-hydroxyvitamin
D (vitamin D) levels were determined using Enzyme-Linked-Immunosorbent Assay (ELISA). A
control group of 41 age and sex matched healthy controls was also included.
Results: The mean level of 25-hydroxyvitamin D (30.65 ± 12.87 ng/ml) was signiﬁcantly
decreased in BD patients compared to the controls (37.98 ± 15.76 ng/ml) (p= 0.02). Signiﬁcant
negative correlations of serum vitamin D levels with patients’ ages (p= 0.03), ESR (p< 0.001),
CRP (p< 0.001) and BDCAF (p= 0.003) were found; whereas, there was no signiﬁcant correla-
tion with disease duration (p= 0.6). In multivariate regression analysis age (p= 0.02), colchicineartment of Rheumatology &
ital, Elqalyubia, Egypt, BO
m (S.S Ganeb).
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152 S.S Ganeb et al.therapy (0.008), ESR (0.02) and CRP (0.03) were found to be the independent effectors on vitamin
D serum levels.
Conclusion: Serum levels of vitamin D were signiﬁcantly lower in BD patients compared to con-
trols. Associations were found between vitamin D levels and age, BDCAF as well as ESR and CRP
in BD patients. Low vitamin D may predispose BD patients to active disease, especially in older
subjects.
 2013 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Behc¸et’s disease (BD) is a systemic relapsing chronic inﬂamma-
tory disease of unknown etiology that presents with recurrent
oral ulcers, genital ulcers, skin lesions and uveitis [1–3]. A wide
range of clinical features are observed, including involvement
of the ophthalmic, musculoskeletal, vascular, central nervous
and gastrointestinal systems [4].
The pathogenesis of BD includes Immune-mediated mech-
anisms and inﬂammatory mediators, hypersensitivity of T lym-
phocytes produced in response to different types of antigens
has a critical role in the pathogenic mechanisms [5–7].
Vitamin D has a major function in maintaining normal cal-
cium and phosphorus blood levels. The best measure of vita-
min D availability is serum levels of 25-hydroxyvitamin D [8]
which is the major circulating form, biologically inactive with
a half-life of about two weeks and reﬂects the amount of vita-
min D entering the circulation that proportionates to the
amount of vitamin D ingested and produced in the skin [9–
11]. It has major biologic activities including cellular prolifer-
ation and differentiation, immune system modulation and
muscle strengthening [12–15].
VitaminD is regarded as an environmental factor essential in
the etiology of T-cell-mediated autoimmune diseases [16]. Poor
vitamin D status is important in the initiation and propagation
of a range of autoimmune diseases [17] like multiple sclerosis,
type 1 diabetes, systemic lupus erythematosus, and rheumatoid
arthritis and is associated with an increased risk of several dis-
eases such as hypertension, infectious diseases, diabetes, cardio-
vascular disease, musculoskeletal disorders, asthma, as well as
several psychiatric conditions such as schizophrenia, depression,
and dementia and solid tumors [18–20]. Few studies have evalu-
ated serum levels of vitamin D in BD.
Some patients with autoimmune diseases have anti-vitaminD
antibodies while, several autoimmune pathways are suppressed
by vitamin D including the Th1, B cells, Th-17, dendritic cell,
and co-stimulatorymolecule systems [21]. VitaminDmetabolites
have direct targets to the adaptive immune system cells [22].
The aim of this study was to investigate serum levels of vita-
min D in patients with BD and to evaluate their relationship to
disease activity as well as different disease measures.
2. Patients and methods
2.1. Subjects
Forty-two BD patients diagnosed according to the Interna-
tional Study Group Criteria for BD (ISGC 1990) [23] and
forty-one age and sex matched healthy volunteers as control
group were included in this study. They were recruited fromthe inpatient and outpatient clinics of Rheumatology, Rehabil-
itation & Physical Medicine, General Medicine, Ophthalmol-
ogy and Dermatology & Andrology of Benha University
hospitals in the period between January 2010 and July 2010.
Patients were excluded from the study if they had other ill-
nesses that might affect the results of the study such as chronic
liver, kidney or endocrine disorders. Subjects taking medica-
tions known to inﬂuence calcium, vitamin D, or phosphorus
metabolism as anticoagulants; anticonvulsants; ﬂuoride; anti-
hypertensive drugs such as B-blockers, diuretics, and calcium
channel blockers were also excluded.
Informed written consents were obtained from all partici-
pants and the study was approved by the local Ethics
Committee.
2.2. Clinical assessments
All BD patients were subjected to the following:
- Detailed history taking
- Thorough clinical examination with stress on dermatologi-
cal, locomotor, vascular and ophthalmologic examination.
- Skin pathergy test was done [24].
- Weights and heights of all subjects were recorded, and body
mass index (BMI) was calculated as weight (kg)/height (m2).
- Assessment of disease activity according to Behc¸et’s Dis-
ease Current Activity Form (BDCAF) score [25].
2.3. Biochemical assessments
- Laboratory investigations: venous blood samples were
obtained from all patients and controls.
The following assessments were done:
- Complete blood picture by coulter counter.
- Erythrocyte sedimentation rate (ESR) by the Westergren
method recorded in mm/1st h.
- C-reactive protein (CRP) by standard nephelometry with
an established normal range of 0–0.8 mg/l.
- Total serum calcium (n= 8.1–10.4 mg/dl), total serum
phosphorus (n= 3.5–5 mg/dl) and total serum alkaline
phosphatase (n= 65–110 IU/L) were assessed spectropho-
tometrically on Hitachi 91.
- Total serum 25-hydroxyvitamin D (vitamin D) was assessed
by Enzyme -Linked- Immunosorbent Assay (ELISA). The
kit was derived from Immundiagnostik AG company had
a DIN IBO 9001 (2000) certiﬁcation (Australian).
Table 2 Clinical manifestations of BD patients.
Clinical manifestation Behc¸et’s disease patients (no = 42)
No (%)
Oral aphthous ulcers 32 (76.2)
Genital ulcers 8 (19.04)
Skin lesions 16 (38.1)
Arthritis 14 (33.33)
Ocular manifestations 16 (38.1)
Vascular lesions 4 (9.5)
Positive pathergy test 8 (19.04)
Vitamin D levels in patients with Behc¸et’s disease: Signiﬁcance and impact on disease measures 153Serum vitamin D levels >30 ng/ml were considered sufﬁ-
cient, while levels of 30 ng/ml or less were considered low.
Statistical analysis: Statistical analysis was performed
using Statistical Package for Social Sciences software
(SPSS), version 13.0. Quantitative variables were presented
as the mean ± SD while qualitative data were expressed
as number and percent. Student‘s (t) test, Z, X2, Pearson’s
correlation coefﬁcient (r) and Mann Whitney U (MWU)
tests were used when appropriate. Multivariate regression
analysis was done to evaluate the effects of different vari-
ables on vitamin D levels. p Value less than 0.05 was con-
sidered signiﬁcant.3. Results
3.1. Demographic and BD related variables
- Patients’ characteristics are represented in (Table 1): The
mean disease duration was 9.77 ± 8.5 years. One patient
(2.4%) was on steroid use of 20 mg/d for the last two
months and 36 (85.7%) patients were on current colchicine
therapy (ranging between 1–1.5 mg/d), two of them were
taking low-dose steroids along with colchicine. Three
patients (7.1%) were on current calcium and vitamin D
supplementation. None of the patients was on bisphospho-
nate therapy.
- The mean BDCAF was 4.5 ± 2.9.
- Patients with BD presented with skin lesions as erytheman-
odosum, sterile pustules or papules in 16 patients (38.1%).
Arthritis was present in 14 patients (33.3%). Ocular disor-
ders [uveitis in 11 patients (26.2%), unilateral optic neuritis
in one patient (2.4%) and retinal vasculitis in one patient
(2.4%)] affected 13 patients (31%). Vascular lesions
[venous thrombosis in three patients (7.1%) and arterial
thrombosis in one patient (2.4%)] occurred in four patients
(9.5%) (Table 2).
- As regards inﬂammatory markers, both ESR and CRP
were signiﬁcantly higher in patients (26.43 ± 14.43 mm/
1st h) and (10.56 ± 8.87 mg/l) than controls (13.35 ±
5.74 mm/1st h) and (4.56 ± 3.57 mg/l), respectively
(Table 3).Table 1 Demographic and clinical data of BD patients and contro
Parameters Patien
Age (years) 35.72 ±
Male/female no 25/17
Disease duration (years) 9.77 ±
Weight (kg) 72.76 ±
Body mass index (kg/m2) 27.38 ±
Postmenopausal no (%) 1 (2.4)
Current calcium and vitamin D supplementation no (%) 3 (7.1)
Patients taking steroid, no (%) 3 (7.1)
Current Colchicine therapy no (%) 36 (85
Current Colchicine dose (mg/day) 1–1.5
Values are expressed as mean ± SD unless otherwise speciﬁed p> 0.05 =3.2. Vitamin D status in BD patients and controls
- There was a statistically signiﬁcant decrease in serum vita-
min D levels (p= 0.02) in patients (30.65 ± 12.87 ng/ml)
compared to controls (37.98 ± 15.76 ng/ml).
- There was a statistically signiﬁcant decrease (z= 2.16,
p= 0.03) of the median values and IQ ranges of serum
vitamin D levels between BD patients (29 and 22.75–39)
and controls (36 and 25.5–48.5), respectively.
- On comparison of serum vitamin D levels according to gen-
der in BD patients and control group, there were no signif-
icant differences of vitamin D levels according to gender in
BD patients [Males: 30.89 ± 11.87; Females: 29.685 ±
12.87 (t= 0.31, p= 0.76)], or in healthy controls
[Males: 38.76 ± 11.67; Females: 36.48 ± 11.65 (t= 0.62,
p= 0.54)].
- A statistically signiﬁcant decrease of vitamin D serum levels
was observed in BD patients with vascular lesions
(t= 3.72, p= 0.001), while there was an insigniﬁcant
decrease of serum vitamin D levels in patients with oral
ulcers (t= 1.5, p= 0.14), skin lesions (t= 0.5, p= 0.62),
arthritis (t= 0.55, p= 0.58), ocular lesions (t= 0.28,
p= 0.79) and positive skin Pathergy test (t= 0.82,
p= 0.42) (Table 4).
- In the group with sufﬁcient serum vitamin D levels, BD
patients had signiﬁcantly lower vitamin D levels compared
to controls (40.4 ± 6.9 ng/ml and 47.8 ± 12.5 ng/ml,
respectively, p= 0.03). In the group with low vitamin D,ls.
ts (no = 42) Controls(no = 41) T p
11.74 34.26 ± 10.82 0.59 0.56
23/18 0.1 0.75
8.5 – – –
14.43 76.67 ± 15.92 1.2 0.24




.7) – – –
– – -
non signiﬁcant.
Table 3 Laboratory data of BD patients and control group.
Parameters Patients (no = 42) Controls (no = 41) T p
ESR (mm/1st hour) 26.43 ± 14.43 13.35 ± 5.74 5.4 0.000*
CRP (mg/l) 10.56 ± 8.87 4.56 ± 3.57 4.04 0.000*
Serum calcium (mg/dl) 8.25 ± 1.21 8.53 ± 1.23 1.1 0.27
P (mg/dl) 3.93 ± 1.92 4.19 ± 1.81 0.63 0.53
ALP (U/L) 98.54 ± 49.98 100.54 ± 50.45 0.18 0.86
Serum vitamin D (ng/ml) 30.65 ± 12.87 37.98 ± 15.76 2.3 0.02*
ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, P: serum phosphorus, ALP: serum alkaline phosphatase.
* = signiﬁcant at p< 0.05, p> 0.05 = non signiﬁcant.
Table 4 Comparison between vitamin D serum levels in BD patients according to the presence and absence of different clinical
manifestations.
Clinical manifestation Vitamin D level (ng/ml) in BD patients (no = 42)
Presence Absence T p
Oral ulcers (no = 32) 29 ± 12.6 35.9 ± 12.7 1.500 0.141
Genital ulcers (no = 8) 31.9 ± 11.8 30.4 ± 13.3 0.297 0.768
Skin lesions (no = 16) 29.4 ± 10.5 31.4 ± 14.3 0.495 0.623
Arthritis (no = 14) 29.1 ± 10.9 31.4 ± 13.9 0.554 0.583
Ocular lesions (no = 16) 29.9 ± 11.1 31.1 ± 14 0.275 0.785
Vascular lesions (no = 4) 10.8 ± 3 32.7 ± 11.7 3.718 0.001*
+ve Pathergy (no = 8) 27.3 ± 11.5 31.4 ± 13.2 0.824 0.415
* = signiﬁcant at p< 0.05 p> 0.05 = non signiﬁcant.
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D compared to the control group (19.6 ± 6.7 ng/ml and
24.2 ± 4.6 ng/ml, respectively, p= 0.034). Seventeen
patients (40.5%) and 28 of controls (68.3%) had sufﬁcient
vitamin D serum levels, while twenty-ﬁve patients (59.5)
and 13 of controls (31.7%) had low vitamin D levels and
the difference was statistically signiﬁcant (X2 = 6.5, p=
0.011) (Figure 1).
- -Comparison of some clinical and laboratory variables in
BD patients according to vitamin D levels revealed statisti-
cally signiﬁcant differences as regards age (t= 2.15,
p= 0.037) and BDCAF (t= 2.77, p= 0.008) (Table 5).
- -On correlating vitamin D serum levels with some variables
among controls, insigniﬁcant correlations were found with
age (r= 0.18, p= 0.27), ESR (r= 0.15, p= 0.36)
and CRP (r= 0.17, p= 0.28).Figure 1 Vitamin D serum levels in BD patients and controls.- -Signiﬁcant inverse correlations of serum vitamin D levels
with patients’ ages (r= 0.54, p= 0.03), ESR (r=
0.59, p< 0.001), CRP (r= 0.53, p< 0.001) (Table 6)
and BDCAF (r= 0.45, p= 0.003, Figure 2) were found.
Whereas, there was insigniﬁcant correlation of serum vita-
min D levels with disease duration (r= 0.1, p= 0.6).
3.3. Effectors of vitamin D levels in BD
- Multivariate regression analysis was performed to deter-
mine the main effectors of vitamin D levels. The variables
included age, disease duration, BDCAF, colchicine ther-
apy, ESR and CRP. Age (p= 0.02), colchicine therapy
(0.008), ESR (0.02) and CRP (0.03) were found to be the
independent effectors of vitamin D levels (Table 7).
4. Discussion
The etiopathogenesis of BD is still unclear, many factors have
been considered including: viral infection, autoimmune dis-
ease, streptococcal-related antigens and genetic factors,
[26,27].
Vitamin D has multiple immunosuppressant properties [20/
9]. Its importance could be explained by previous reports stat-
ing that it signiﬁcantly decreases the incidence and/or progres-
sion of autoimmune diseases [28,29].
This study aimed to investigate serum levels of vitamin D in
patients with BD and to evaluate their relationship to disease
activity as well as different disease measures.
Table 5 Comparison of some variables in BD patients according to vitamin D serum levels.
Variable BD patients (no = 42) according to vitamin D level Test value p
Suﬃcient (>30 ng/ml) (no = 17) Low (6 30 ng/ml) (no = 25)
Age (years) 32.8 ± 7.7 37.6 ± 6.5 t= 2.15 0.037*
Disease duration (years) 6.65 ± 4.56 9.83 ± 6.37 t= 1.76 0.09
Current smoker no (%) 1 (5.9) 6 (24) Z= 1.5 0.12
Current steroid no (%) 1 (5.9) 2 (8) Z= 0.26 0.79
Current Colchicine no (%) 13 (76.5) 23 (92) Z= 1.4 0.15
BDCAF 3.1 ± 2.3 5.4 ± 2.9 t= 2.77 0.008*
Values are expressed as mean ± SD unless otherwise speciﬁed.
BDCAF: Behc¸et’s Disease Current Activity Form.
* Signiﬁcant at p< 0.05 p> 0.05 = non signiﬁcant.
Table 6 Correlations between vitamin D serum levels and
variables in BD patients.
Variable R p-value
Age (years) 0.54 0.03*
Disease duration (years) 0.1 0.6
BDCAF 0.45 0.003*
ESR (mm/1st hour) 0.59 0.000*
CRP (mg/l) 0.53 0.000*
ESR: erythrocyte sedimentation rate, CRP: C- reactive protein,
BDCAF: Behc¸et’s Disease Current Activity Form.
* Signiﬁcant at p< 0.05 p> 0.05 = non signiﬁcant.
Figure 2 Correlations of serum vitamin D levels with patients’
Behc¸et’s Disease Current Activity Form (BDCAF).
Table 7 Multivariate regression analysis in BD patients.
Beta p
Age (years) 0.67 0.02*
Disease duration (years) 0.03 0.86
Colchicine therapy 0.86 0.008*
ESR (mm/1st hour) 0.37 0.02*
CRP (mg/L) 0.31 0.03*
BDCAF 0.17 0.21
ESR: erythrocyte sedimentation rate, CRP: C-reactive protein,
BDCAF: Behc¸et’s Disease Current Activity Form.
* = signiﬁcant at p< 0.05 p> 0.05 = non signiﬁcant.
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vitamin D were signiﬁcantly decreased (p= 0.02) in BD pa-
tients compared to healthy controls. Seventeen patients
(40.5%) and 28 of controls (68.3%) had sufﬁcient vitamin D
serum levels, while 25 patients (59.5%) and 13 of controls
(31.7%) had low vitamin D levels and the difference was statis-
tically signiﬁcant (p= 0.011). Decreased serum levels of vita-
min D have been reported in BD [30] and several other
autoimmune diseases including rheumatoid arthritis [16,31],
systemic lupus erythematosus [17,32], multiple sclerosis [33]
and undifferentiated connective tissue disease [34]. Those stud-
ies suggested that down-regulation of vitamin D is almost in-
volved in the pathogenesis of these diseases.
Colin et al. [31] stated that vitamin D and vitamin D
analogs’ supplementation contribute to the bone-preserving
effects and could have a role when combined with corticoste-roids in the prevention of focal bone erosions in RA. They also
reported that these ﬁndings may be effective for other chronic
inﬂammatory autoimmune diseases treated with corticoste-
roids.
Several factors decrease vitamin D levels. Reduced skin
synthesis and absorption of vitamin D occur with the aging
process [32], obesity results in vitamin D sequestration in body
fat [35], smoking impairs 1-alpha-hydroxylation [36] and en-
hances hepatic degradation of estrogen which alters metabo-
lism of vitamin D [37], corticosteroids accelerate vitamin D
catabolism [38] and estrogen deﬁciency increases parathor-
mone hormone leading to decreased vitamin D [39].
This study revealed a statistically signiﬁcant decrease of
vitamin D serum levels in BD patients with vascular lesions
compared to those patients without vascular lesions (p=
0.001). This conﬁrmed previous studies that found vitamin D
deﬁciency to be associated with cardiovascular events such as
myocardial infarction or stroke [40,41].
We found a signiﬁcant negative association between vita-
min D serum levels and patients’ ages (p= 0.03). Several pre-
vious studies found a negative correlation between vitamin D
serum levels and patients’ age [42–45]. Lerner et al. [21] re-
ported that age is the major factor affecting serum vitamin
D levels. Yu et al. [46] stated that in aged BD patients, calcium
status of the host may inﬂuence the effect of vitamin D on
immunity.
In the present study, there were signiﬁcant negative correla-
tions of vitamin D serum levels with BD patients’ ESR
(p< 0.001) and CRP (p< 0.001). These ﬁndings were in agree-
ment with those of Do et al. [30] who found decreased serum
vitamin D levels were inversely correlated with ESR and CRP
levels. On the other hand Karaty et al. [47] demonstrated that
156 S.S Ganeb et al.there was no correlation between vitamin D levels and ESR or
CRP levels in BD patients. Timms et al. [48], in their study on
healthy adults revealed that CRP levels were decreased by
23% in hypovitaminosis Dpatients who received approximately
547 IU of vitamin D daily for 2.5 years and suggested a dose-
dependent anti-inﬂammatory effect of vitamin D.
The results of this study exhibited signiﬁcant negative
correlations of vitamin D serum levels with BDCAF (p=
0.003). Our results go hand in hand with those of Do et al.
[30] who showed decreased serum vitamin D levels in active
BD patients compared with controls and suggested that vita-
min D deﬁciency is a possible risk factor for BD activity and
disturbance in the inﬂammatory condition. In the same con-
text, Hamzaoui and his colleagues [49] found that in active
BD patients, there were signiﬁcantly inverse correlations be-
tween vitamin D levels and both CRP and ESR expression,
indicating that disease activity is associated with lower vitamin
D serum levels while, no correlations were observed in healthy
controls and inactive BD patients. They also observed a signif-
icant and inverse correlation between vitamin D of active BD
patients and age.
Dusso et al. [50] reported that a low vitamin D level is pos-
sibly an indicator for the inﬂammatory process as Inﬂamma-
tion itself potentially enhances vitamin D catabolism.
In multivariate regression analysis, age (p= 0.02), colchi-
cine therapy, (0.008), ESR (0.02) and CRP (0.03) were found
to be independent effectors of vitamin D levels.
Karatay and his associates [47], in multivariate regression
analysis, stated that smoking, alcohol intake, and use of col-
chicine were the main predictors of vitamin D levels, although
the effects of colchicine on vitamin D levels have not yet been
fully deﬁned.
In conclusion, this study demonstrated that serum levels of
vitamin D were signiﬁcantly lower in BD patients compared to
controls. Associations were found between vitamin D levels
and age, disease activity as well as ESR and CRP in BD pa-
tients. Low vitamin D may predispose those patients to active
disease, especially in older subjects. More studies are required
to determine whether treatment with vitamin D would have
beneﬁcial effects on patients with BD.
Conﬂict of interest
All the authors responsible for this work declare no conﬂict of
interest.Acknowledgment
We thank Prof Dr Samia Abdelmoneim for her unbounded
support and revision of this work.References
[1] Kaburaki T, Araki F, Takamoto M, Okinaga K, Yoshida A,
Numaga J, et al. Best-corrected visual acuity and frequency of
ocular attacks during the initial 10 years in patients with Behc¸et’s
disease. Graefes Arch Clin Exp Ophthalmol 2010;248:709–14.
[2] Hong SN, Park JC, Yoon NS, Lee SR, Kim KH, Hong YJ, et al.
Carotid artery intima-media thickness in Behc¸et’s disease patientswithout signiﬁcant cardiovascular involvement. Korean J Intern
Med 2008;23:87–93.
[3] Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M,
Takeno M, et al. Clinical characteristics of neuro-Behc¸et’s disease
in Japan: a multicenter retrospective analysis. Mod Rheumatol
2012;22:405–13.
[4] Rhee MY, Chang HK, Kim SK. Intima-media thickness and
arterial stiffness of carotid artery in Korean patients with Behc¸et’s
disease. J Korean Med Sci 2007;22(3):387–92.
[5] Kaneko F, Togashi A, Saito S, Sakuma H, Oyama N, Nakamura
K, et al. Behc¸et’s disease (Adamantiades-Behc¸et’s disease). Clin
Dev Immunol 2011;2011:681–956.
[6] Mendoza-Pinto C, Garcı´a-Carrasco M, Jime´nez-Herna´ndez M,
Jime´nez Herna´ndez C, Riebeling-Navarro C, Nava Zavala A,
et al. Etiopathogenesis of Behc¸et’s disease. Autoimmun Rev
2010;9(4):241–5.
[7] Kapsimali VD, Kanakis MA, Vaiopoulos GA, Kaklamanis PG.
Etiopathogenesis of Behc¸et’s disease with emphasis on the role of
immunological aberrations. Clin Rheumatol 2010;29(11):1211–6.
[8] Cutolo M, Otsa K, Paolino S, Yprus M, Veldi T, Seriolo B.
Vitamin D involvement in rheumatoid arthritis and systemic lupus
erythematosus. Ann Rheum Dis 2009;68(3):446–7.
[9] Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity:
new aetiological and therapeutic considerations. Ann Rheum Dis
2007;66:1137–42.
[10] Bringhurst FR, Demay MB, Kronenberg HM. Hormones and
disorders of mineral metabolism. In: Kronenberg HM, Melmed S,
Polonsky KS, Larsen PR, editors. Williams textbook of endocri-
nology. Philadelphia: Elsevier; 2008.
[11] Leventis P, Patel S. Clinical aspects of vitamin D in the
management of rheumatoid arthritis. Rheumatology 2008;47:
1617–21.
[12] Haroon M, Bond U, Quillinan N, Phelan MJ, Regan MJ. The
prevalence of vitamin D deﬁciency in consecutive new patients
seen over a 6-month period in general rheumatology clinics. Clin
Rheumatol 2011;30(6):789–94.
[13] DeLuca HF. Overview of general physiologic features and
functions of vitamin D. Am J Clin Nutr 2004;80:1689S–96S.
[14] Penna G, Roncari A, Amuchastegui S, Daniel KC, Berti E,
Colonna M, et al. Expression of the inhibitory receptor ILT3 on
dendritic cells is dispensable for induction of CD4+Foxp3+reg-
ulatory T cells by 1,25-dihydroxyvitamin D3. Blood 2005;106:
3490–7.
[15] Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T,
Dawson-Hughes B. Estimation of optimal serum concentrations
of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin
Nutr 2006;84:18–28.
[16] Cutolo M, Otsa K. Review: vitamin D, immunity and lupus.
Lupus 2008;17:6–10.
[17] Ben-Zvi I, Aranow C, Mackay M, Stanevsky A, Kamen DL,
Marinescu LM, et al. The impact of vitamin D on dendritic cell
function in patients with systemic lupus erythematosus. PLoS One
2010;5(2):e9193.
[18] Shoenfeld N, Amital H, Shoenfeld Y. The effect of melanism and
vitamin D synthesis on the incidence of autoimmune disease. Nat
Clin Pract Rheumatol 2009;5:99–105.
[19] Toubi E, Shoenfeld S. The role of vitamin D in regulating immune
responses. Isr Med Assoc J 2010;12:174–5.
[20] Holick MF, Vitamin D. Photobiology, metabolism, mechanism of
action, and clinical applications. In: Favus MJ, editor. Primer on
the metabolic bone diseases and disorders of mineral metabolism.
Washington, DC: American Society for Bone and Mineral
Research; 2003. p. 129–37.
[21] Lerner A, Shapira Y, Agmon-Levin N, Pacht A, Ben-Ami Shor D,
Lo´pez HM, et al. The clinical signiﬁcance of 25OH-vitamin D
status in celiac disease. Clin Rev Allergy Immunol 2012;42:
322–30.
Vitamin D levels in patients with Behc¸et’s disease: Signiﬁcance and impact on disease measures 157[22] Peelen E, Knippenberg S, Muris AH, Thewissen M, Smolders J,
Tervaert JW, et al. Effects of vitamin D on the peripheral
adaptive immune system: a review. Autoimmun Rev 2011;10(12):
733–43.
[23] International Study Group for Behc¸et’s disease. Criteria for
diagnosis of Behc¸et’s disease. Lancet 1990;335:1078–80.
[24] Altac¸ M, Tu¨zu¨n Y, Yurdakul S, Binyildiz P, Yazici H. The
validity of the pathergy test (non-speciﬁc skin hyperreactivity) in
Behc¸et’s disease: a double-blind study by independent observers.
Acta Derm Venereol 1982;62(2):158–9.
[25] Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA
Silman AJ. Behc¸et’s disease: evaluation of a new instrument to
measure clinical activity. Rheumatology 1999;38:728–33.
[26] Namba K, Ueno T, Okita M. Behc¸et’s disease and streptococcal
infection. Jpn J Ophthalmol 1986;30(4):385–401.
[27] Ideguchi H, Suda A, Takeno M, Ueda A, Ohnu S, Ishigatsubo Y.
Behc¸et disease: evolution of clinical manifestations. Medicine
2011;90:125–32.
[28] Adorini L. Selective immunointervention in autoimmune diseases:
lessons from multiple sclerosis. J Chemother 2001;13:219–34.
[29] Adorini L. Immunomodulatory effects of vitamin D receptor
ligands in autoimmune diseases. Int Immunopharmacol 2002;2:
1017–28.
[30] Do JE, Kwon SY, Park S, Lee ES. Effects of vitamin D on
expression of Toll-like receptors of monocytes from patients with
Behc¸et’s disease. Rheumatology (Oxford) 2008;47:840–8.
[31] Colin EM, Asmawidjaja PS, van Hamburg JP, Mus AM, van
Driel M, Hazes JM, et al. 1,25-Dihydroxyvitamin D3 modulates
Th17 polarization and interleukin-22 expression by memory T
cells from patients with early rheumatoid arthritis. Arthritis
Rheum 2010;62(1):132–42.
[32] Wu PW, Rhew EY, Dyer AR, Dunlop DD, Langman CB, Price
H, et al. 25-Hydroxyvitamin D and cardiovascular risk factors in
women with systemic lupus erythematosus. Arthritis Rheum
2009;61(10):1387–95.
[33] Soilu-Ha¨nninen M, Laaksonen M, Laitinen I, Eralinna JP, Lilius
EM, Mononen I. A longitudinal study of serum 25-hydroxyvita-
min D and intact parathyroid hormone levels indicate the
importance of vitamin D and calcium homeostasis regulation in
multiple sclerosis. J Neurol Neurosurg Psychiatry 2008;79:152–7.
[34] Zold E, Szodoray P, Gaal J, Kappelmayer J, Csathy L, Gyimesi E,
et al. Vitamin D deﬁciency in undifferentiated connective tissue
disease. Arthritis Res Ther 2008;10(5):R123.
[35] Holick MF. Vitamin D deﬁciency. N Engl J Med 2007;357:
266–81.
[36] Brot C, Ju`rgensen N, Su`rensen O. The inﬂuence of smoking on
vitamin D status and calcium metabolism. Eur J Clin Nutr
1999;53:920–6.[37] Jensen GF, Meinecke B, Boesen J, Transbol I. Does 1,25-(OH)2
D3 accelerate spinal bone loss? Clin Orthop 1985;192:215–21.
[38] Kamen DL, Tangpricha V. Vitamin D and molecular actions on
the immune system: modulation of innate and autoimmunity. J
Mol Med (Berl) 2010;88(5):441–50.
[39] Ooms ME, Lips P, Roos JC, Van Der Vijgh WJ, Popp Snijders C,
Bezemer PD, et al. Vitamin D status and sex hormone binding
globulin: determinants of bone turnover and BMD in elderly
women. J Bone Miner Res 1995;10:1177–84.
[40] Dobnig H et al. Independent association of low serum 25- hydrox-
yvitamin D and 1,25-dihydroxyvitamin D levels with all cause and
cardiovascular mortality. Arch Intern Med 2008;168(12):p–9.
[41] Kilkkinen A et al. Vitamin D status and the risk of cardiovascular
disease death. Am J Epidemiol 2009;170(8):1032–9.
[42] Ginde AA, Liu MC, Camargo Jr CA. Demographic differences
and trends of vitamin D insufﬁciency in the US population 1988–
2004. Arch Intern Med 2009;169(6):626–32 [23].
[43] Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes
B, Eisman JA, et al. Global vitamin D status and determinants of
hypovitaminosis D. Osteoporos Int 2009;20(11):1807–20.
[44] Hirani V, Tull K, Ali A, Mindell J. Urgent action needed to
improve vitamin D status among older people in England! Age
ageing 2010;39(1):62–8.
[45] Lagunova Z, Porojnicu AC, Lindberg F, Hexeberg S, Moan J.
The dependency of vitamin D status on body mass index, gender,
age, and season. Anticancer Res 2009;29(9):3713–20.
[46] Yu S, Cantorna MT. The vitamin D receptor is required for iNKT
cell development. Proc Natl Acad Sci USA 2008;105:5207–12.
[47] Karatay S, Yildirim K, Karakuzu A, Kiziltunc A, Engin RI, Eren
YB, et al. Vitamin D status in patients with Behc¸et’s disease.
Clinics 2011;66(5):721–3.
[48] Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG,
Syndercombe-Court D, et al. Circulating MMP9, vitamin D and
variation in the TIMP-1 response with VDR genotype: mecha-
nisms for inﬂammatory damage in chronic disorders? Q J Med
2002;95:787–96.
[49] Hamzaoui K, Ben Dhifallah I, Karray E, Sassi FH, Hamzaoui A.
Vitamin D modulates peripheral immunity in patients with
Behc¸et’s disease. Clin Exp Rheumatol 2010;28(4):S50–7 [S(60)].
[50] Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L,
Shapiro S. Gamma-interferon-induced resistance to 1,25-(OH)2
D3 in human monocytes and macrophages: a mechanism for the
hypercalcemia of various granulomatoses. J Clin Endocrinol
Metab 1997;82:2222–32.
